Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to support clinical choice in asthma treatment in the provision of biologic treatments, as recommended in the APPG report, entitled Improving Asthma Outcomes in the UK.

There has been significant increase in the use of biologics in the last three years. The decision to start a biologic treatment for asthma is made by specialist severe asthma multi-disciplinary teams (MDT) based in severe asthma centres on clinical grounds. The MDT considers all aspects of the patients’ illness, efficacy of current treatments and other treatment options. Patients receiving biologics are closely monitored to ensure that they are receiving the right treatment to help manage their symptoms.